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Abstract
Background: Diagnosis of Trypanosoma cruzi infection by direct pathogen detection is complicated by the low parasite
burden in subjects persistently infected with this agent of human Chagas disease. Determination of infection status by
serological analysis has also been faulty, largely due to the lack of well-characterized parasite reagents for the detection of
anti-parasite antibodies.
Methods: In this study, we screened more than 400 recombinant proteins of T. cruzi, including randomly selected and those
known to be highly expressed in the parasite stages present in mammalian hosts, for the ability to detect anti-parasite
antibodies in the sera of subjects with confirmed or suspected T. cruzi infection.
Findings: A set of 16 protein groups were identified and incorporated into a multiplex bead array format which detected
100% of .100 confirmed positive sera and also documented consistent, strong and broad responses in samples undetected
or discordant using conventional serologic tests. Each serum had a distinct but highly stable reaction pattern. This
diagnostic panel was also useful for monitoring drug treatment efficacy in chronic Chagas disease.
Conclusions: These results substantially extend the variety and quality of diagnostic targets for Chagas disease and offer a
useful tool for determining treatment success or failure.
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Introduction
Chagas disease, a consequence of infection by the protozoan
parasite Trypanosoma cruzi, affects up to 20 million individuals
primarily in the Americas where the insect vectors are present and
where zoonotic transmission cycles guarantee a steady source of
parasites. T. cruzi infection has its greatest human impact in areas
of Latin America where housing conditions bring people, infected
animals, and vector insects into close proximity [1]. In addition,
increasing travel and immigration has brought T. cruzi infection
into the spotlight globally, even in areas where transmission has
previously been absent or very low. In these latter situations,
congenital and transfusion/transplantation-related transmissions
are becoming recognized as significant threats [2,3,4].
Diagnosis of T. cruzi infection is challenging for a number of
reasons. The initial infection is seldom detected except in cases
where infective doses are high and acute symptoms very severe, as
in localized outbreaks resulting from oral transmissions [5,6,7].
Classical signs of inflammation at proposed sites of parasite entry
(e.g. ‘‘Roman ˜a’s sign’’) or clinical symptoms other than fever, are
infrequently reported [8]. As a result, diagnosis is very rarely
sought early in the infection, when direct detection of parasites
may be possible. In the vast majority of human cases, T. cruzi
infection evolves undiagnosed into a well-controlled chronic
infection wherein circulating parasites or their products are
difficult to detect even with the use of amplification techniques.
A ‘‘conclusive’’ diagnosis of T. cruzi infection is often reached only
after multiple serological tests and in combination with epidemi-
ological data and (occasionally) clinical symptoms.
Unfortunately, multiple studies from geographically distinct
areas and utilizing a wide range of tests and test formats have
shown current diagnostics to be far from dependable
[9,10,11,12,13,14,15,16,17,18,19] Many of the most widely
employed serological tests, including one recently licensed by the
United States Food and Drug Administration for use as a blood
screening test in the U.S. [20], use crude or semi-purified parasite
preparations, often derived from parasite stages present in insects
but not in infected humans. Other tests have incorporated more
defined parasite components, including multiple fusion proteins
containing epitopes from various parasite proteins, which,
individually have shown some promise as diagnostics [13,21,22].
Unfortunately, in the absence of a true gold standard, the
sensitivity of new tests is generally determined using sera that have
been shown to be unequivocally positive on multiple other
serologic tests, but rarely with sera that are borderline or equivocal
on one or more tests. This approach assures only that the test
www.plosntds.org 1 October 2008 | Volume 2 | Issue 10 | e316being evaluated is no worse, but not necessarily any more sensitive,
than the existing tests.
In this study, we sought to improve upon current diagnostics for
T. cruzi infection by screening for diagnostic candidates that
displayed the ability to detect infection in subjects that went
undetected or gave discordant results using other conventional
serologic tests. The end result is the identification of a panel of
recombinant proteins that more reliably detects T. cruzi infection
than do a combination of existing conventional tests. Additionally,
we show that a multiplex assay utilizing this diagnostic panel has
utility in monitoring drug treatment efficacy in chronic Chagas
disease.
Methods
Parasites, gene selection and cloning
T. cruzi epimastigotes of the SylvioX10/4 (original source human,
Brazil), CL Brener (insect, Brazil), Brazil (human, Brazil), CL,
Tulahuen (insect, Chile), M83, M91 (both from human, Argentina)
and Chapulin (dog, Argentina) isolates were maintained in
logarithmic phase growth [23] and used as a source of genomic
DNA. Primer sets incorporating lambda phage recombination sites
flanking the 18–21 base gene-specific sequence (excluding both start
and stop codons), were designed for each gene of interest, the genes
cloned by PCR from the pooled DNA of the 8 T. cruzi isolates, and
Gateway adapted gene product inserted into the pDONR-201
plasmid (Invitrogen, Carlsbad, CA). To speed the cloning process
while improving our chances of cloning full-length non-mutated
genes, at least 10 clones positive for the appropriate sized insert were
pooledforeachgene.T.cruzilysatefromBrazilstrainamastigoteand
trypomastigotes was prepared as previously described by 4 freeze-
thaw cycles followed by sonication [24].
pDEST-PTD4 Construction
The pDEST-PTD4 protein expression vector was created from
pTAT-HA [25] by replacing the BamHI-flanked TAT sequence
with a BamHI-flanked PTD-4 encoding sequence [26], followed
by Gateway (Invitrogen)- adaptation of the plasmid utilizing the
NcoI and XhoI cloning sites. The Gateway cloning cassette was
PCR amplified from pDEST-YFP (gift from Dr. Boris Striepen,
University of Georgia, GA).
Protein production and purification
Genes in pDONR plasmids were transferred to pDEST-PTD4
via a Gateway LR reaction and the proteins expressed in
BL21(DE3)pLysS cells were extracted by sonication in 8 M urea,
20 mM HEPES, 100 mM NaCl, pH 8.0 containing 15 mM
imidazole. The lysate was then applied to TALON Metal Affinity
Resin (BD Biosciences Clonetech, Palo Alto, CA) and bound
protein was eluted with 250 mM imidazole. Imidazole was
removed on PD-10 desalting columns (GE Healthcare, Piscat-
away, NJ) and protein concentration was estimated using a
modified Bradford assay. Proteins were diluted to 10 mg/mL (in
8 M urea) and stored in 1 mL aliquots at 220 C until use.
Human Sera
Sera were obtained from individuals living in areas of Santiago
del Estero, Argentina endemic for Trypanosoma cruzi and were
analyzed using conventional serologic tests (e.g. immunofluores-
cence assay (IFI), hemagglutination (HAI), and ELISA to detect
IgG [27]) performed at the Diagnostic Department of the Instituto
Nacional de Parasitologı ´a ‘‘Dr. Mario Fatala Chabe ´n’’ and in our
laboratory by a commercial ELISA serodiagnostic kit (Hemagen
Diagnostics, Columbia, MD). The latter assay was carried out as
per the manufacturer’s instructions with a positive response
defined as 10% above the cutoff (0.250+mean of negative control
absorbencies). Three serum pools were created: a ‘‘sero-negative’’
pool consists of 4 sera negative on all assays; a ‘‘borderline
positive’’ pool made up of 5 sera with a response at or just above
the equivocal zone of the Hemagen test (between cutoff and below
cutoff+10%); a ‘‘strong positive’’ pool containing 7 sera that gave
unequivocally positive responses on all tests. True negative
controls (16 total) were obtained from volunteer donors who were
not from endemic areas (North America and Buenos Aires). Sera
(from 175 total subjects) used for subsequent analysis of individual
proteins were obtained from T. cruzi-infected adult volunteers aged
29 to 61 recruited through the Chagas Disease Section of the
Cardiology Department, Hospital Interzonal General de Agudos
‘‘Eva Pero ´n’’, Buenos Aires, Argentina and infection status was
determined serologically as described above. In some cases,
subjects treated by a 30 day course of benznidazole as previously
described [28] donated serum samples prior to treatment and at
regular intervals following treatment. In all cases, sera were
collected from clotted blood obtained by venapuncture, then
aliquoted and stored at 270uC and subjected to a minimum
possible number of freeze/thaw cycles. The protocols were
approved by the IRBs of the University of Georgia and the
Hospital Interzonal General de Agudos ‘‘Eva Pero ´n’’ and signed
informed consent was obtained from all individuals prior to
inclusion in the study.
Multiplex Assay
Recombinant proteins were attached to Liquichip Ni-NTA
beads (Qiagen) or Beadlyte Nickel Beads (Upstate Biotechnology)
by incubating excess protein (10 ug/ml) with an equal volume of
beads overnight at 4uC in the dark. The sets of distinct addressable
beads, each with a different protein attached, were pooled in equal
volumes along with positive and negative control beads, consisting
respectively of Liquichip Carboxy Beads (Qiagen) coupled to T.
cruzi lysate and Liquichip Ni-NTA beads coated with recombinant
HIS-tagged enhanced green fluorescent protein (EGFP). Sera at
Author Summary
The diagnosis of Trypanosoma cruzi infection (the cause of
human Chagas disease) is difficult because the symptoms
of the infection are often absent or non-specific, and
because the parasites themselves are usually below the
level of detection in the infected subjects. Therefore,
diagnosis generally depends on the measurement of T.
cruzi–specific antibodies produced in response to the
infection. However, current methods to detect anti–T. cruzi
antibodies are relatively poor. In this study, we have
conducted a broad screen of .400 T. cruzi proteins to
identify those proteins which are best able to detect anti–
T. cruzi antibodies. Using a set of proteins selected by this
screen, we were able to detect 100% of .100 confirmed
positive human cases of T. cruzi infection, as well as
suspect cases that were negative using existing tests. This
protein panel was also able to detect apparent changes in
infection status following drug treatment of individuals
with chronic T. cruzi infection. The results of this study
should allow for significant improvements in the detection
of T. cruzi infection and better screening methods to avoid
blood transfusion–related transmission of the infection,
and offer a crucial tool for determining the success or
failure of drug treatment and other intervention strategies
to limit the impact of Chagas disease.
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using standard procedures [29]. Antibody binding to individual
beads was detected with donkey anti-human IgG (H+L)
conjugated to phycoerythrin (cat no. 709-116-149, Jackson
ImmunoResearch, West Grove, PA) and quantified on a BioPlex
Suspension Array System (BioRad).
Statistical Analysis
Serum samples were assayed in duplicate and the weighted mean
fluorescence intensity (MFI) was calculated for a minimum of 30
beads per determination. The ratio of the specific MFI for each
antigen to the MFI of the negative control (GFP- or OVA-coupled)
protein was then calculated for each serum and antigen in the assay.
Values above the mean plus 4 standard deviations of a minimum of
sixteen true negative sera run in the same assay, and individually
determined for each antigen, were considered positive.
Results
As part of a vaccine discovery effort, nearly 1500 genes from T.
cruzi have been cloned into Gateway entry vector plasmids that
allow them to be easily moved into a range of other plasmids.
Genes were selected for cloning using a variety of criteria, initially
including known expression in T. cruzi lifecycle stages that are
present throughout infection in mammals (i.e. trypomastigotes and
amastigotes), high likelihood of being surface expressed or secreted
and expected presence in the genome at low copy number. With the
completionofthe T.cruzigenomesequencing project[30]and whole
organism proteome analysis [31] the additional criterion of being
relatively high in abundance in the proteomes of trypomastigotes
and amastigotes was added as a basis for selection. Recombinant
proteinsproduced inE.colihadN-terminaltagscarryingthe6XHis-,
PTD [26] and HA- tags for purification, protein translocation, and
identification, respectively were captured by Ni-coupled Luminex
beadsfor use ina multiplex bead arrayassay.The Luminexplatform
is based upon the use of internally stained and individually
addressable bead sets which can be coupled with different molecules
(in our cases, T. cruzi proteins) and then used to measure the
concentration of multiple analytes (antibodies specific for the
individual proteins) in a solution (serum). Identification of the
distinct beads and quantitation of antibody binding is accomplished
by flow cytometry. As many as 100 different analytes can be
simultaneously assayed in ,100 ul sample.
Selection of the diagnostic panel
The initial selection screen (Figure 1) used approximately 420
proteins produced in pools of 8–10 proteins each. Production of
pooled proteins was accomplished by moving sets of genes in batch
into the PTD-4 expression plasmid and was confirmed by SDS-
PAGE analysis (Figure 2). In addition to the individual or pooled
Figure 1. Screening process for the high-throughput selection of diagnostic proteins for detection of T. cruzi infection.
doi:10.1371/journal.pntd.0000316.g001
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negative control recombinant protein (ovalbumin or GFP)
expressed from the PTD-4 plasmid as well as a lysate of
trypomastigotes and amastigotes of T. cruzi that had been
chemically coupled to BioPlex beads.
To screen the pooled proteins we also took a pooling approach
by assembling sera from subjects with and without documented
infection with T. cruzi. Screening of 51 protein pools revealed 21
pools that were reactive with one or more of the serum pools 1–3
(Figure 1). Reactive pools were then broken down into their
individual constituent proteins; a total of 140 proteins were
successfully expressed and individually rescreened with the serum
pools, ultimately resulting in the selection of 55 proteins with
serodiagnostic potential (Figure 1 and Table 1). An additional
22 proteins that were either identified as high-abundance proteins
using proteome analysis [31] and/or as being unique to T. cruzi
(and thus not encoded in the T. brucei or Leishmania major genomes)
were then screened using the pooled sera, and 4 of these 22 were
found to be reactive with one or more serum pools. Of the
resulting 59 candidate proteins recognized by antibodies in the
serum of T. cruzi-infected subjects, 20 were subsequently excluded
from further testing either because they exhibited significant
reactivity with sera from the true negative pool, or because they
interfered with other beads in the multibead assays, perhaps
because of protein-protein interactions. Preference was also given
to T. cruzi proteins that detected antibodies in sera from the
‘‘borderline’’ pools. Ultimately 39 proteins (in bold in Table 1)
were selected for extensive further testing with a wider array of
individual subject sera.
Although the Luminex bead array technology theoretically
accommodates up to 100 distinct, addressable beads in a single
well – and thus the ability to assay up to 100 individual proteins -
at the time of this work only 17 distinct beads were available with
the ability to capture his-tagged proteins. Thus our goal in the
second part of the screen was to identify a set of the 16 best T. cruzi
proteins (allowing a bead for a control non-T. cruzi protein). The
39 candidate diagnostic proteins were tested in sets of 8–15, with
each protein on a separate bead and with a negative control bead
(HIS-tagged ovalbumin (OVA)) and a positive control bead (T.
cruzi lysate) included in each assay sample. Between 38 and 48
individual sera from endemic subjects were used to test each
protein. These sera are grouped as ‘‘uniformly positive’’ (reactive
on all conventional serological tests), ‘‘inconclusive’’ (positive on at
least one, but not all, conventional serologic tests), and ‘‘negative
by conventional tests’’, and ‘‘known negative’’ (from residents of
North America). Figure 3 shows a representative set of 29
proteins tested with 54 individual sera and indicates the range of
reactivities of both sera and proteins. In addition to providing the
basis on which to select the top proteins, this analysis also revealed
that among the 30 sera that were inconclusive or negative on
conventional tests, nearly half (14 of 30) had substantial reactivity
to 3 or more recombinant T. cruzi proteins but not with the control
OVA protein.
Following repeated screening, 16 proteins were selected to be
part of the diagnostic panel (underlined in Table 1). DNA
sequencing and mass spectrometric analysis confirmed the identity
of each gene and protein and determined that one of the
preparations contained two distinct proteins (calmodulin and an
ATPase) and a second contained a mixture of related TolT
proteins. This protein set was then used to screen a larger set of
sera, most from chronically infected subjects living in Buenos
Aires, and the percentage of these proteins reactive with 121 sera
from well-characterized subjects was determined (Table 1). A
serum was determined to be positive for any particular test antigen
if the average luminescence (MFI) was .4 standard deviations
above that of a set of true negative sera run in the same assay.
Across all experiments, for the 19 true negative sera assayed
multiple times (142 sample runs tested on 16 protein preparations
for a total of 2272 determinations), none had S.D..4 and only 17
of the 2272 determinations were .3 S.D. above the average
negative serum values (and 9 of these 17 were from one serum
sample reactive with the same antigen in multiple tests). Thus, this
was a highly stringent cutoff. Sera from all 121 of the confirmed
chronically infected subjects reacted with at least 1 of the 16
recombinant protein preparations at the .4 S.D. cutoff and all but
7 reacted with .1 protein. As shown in Table 1, 6 of the 16 of the
antigens each detected .50% of the sera and 3 antigens
approached a 75% detection rate. Of the 121 sera tested, 118
would have been detected as positive using only 4 of the antigens
and 100% would be detected using as few as 7 antigens.
Borderline samples
We then used our 16 bead multiplex test to attempt to resolve
questionable infection status in subjects due to discordant results
on conventional tests (Figure 4). In this analysis, a cutoff for
reactivity for each protein in the panel was set at the MFI plus 4
SD above the mean of a set of 16 negative sera. For comparison,
the result of multiplex analysis of a pool of strongly positive sera
assayed on different days is also shown. The strong positive serum
pool showed excellent cross-assay consistency with 11 of the 16
protein preparations positive on each of 8 assays and consistent
negative reactivity with 3 of 16. Antibodies to the remaining 2
proteins were also detected but at a lower level that sometimes fell
below the strict cutoff of 4 S.D. above the mean. The sera
classified as ‘‘conventional seronegative with no other evidence of
infection’’ broke into 2 groups based upon the results of the
multiplex test. Eight of the 16 failed to react with any of the 16
protein panel (although several reacted with the T. cruzi lysate)
while the remaining 8 reacted with 2–4 proteins. A similar nearly
Figure 2. SDS-PAGE gel of production of pooled protein. Sets of
6–8 genes were moved in pools from pDONR entry plasmids into
pDEST-PTD4 via a Gateway LR reaction (Invitrogen) and the resulting
plasmids transformed into BL21(DE3)pLysS cells for protein production.
Recombinant HIS-tagged proteins were purified on Co+2 affinity resin
and the bound proteins analyzed by SDS-PAGE. Protein pools depicted
in lanes 1–5 were generated from the pooling of 8 genes, while lanes 6,
7 and 8 were derived from 7, 6, and 6 genes respectively. Lane ‘‘S’’
contained molecular weight standards (BenchMark Prestained Protein
Standard; Invitrogen). Overall, approximately 80% of genes yielded
proteins when expressed as pools.
doi:10.1371/journal.pntd.0000316.g002
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Gene Id Gene name(s) Notes
% reactive with 121
known positive sera
Tc00.1047053506391.10,
Tc00.1047053509233.180
calmodulin and ATPase beta subunit high abundance 32.23%
Tc00.1047053507029.30 heat shock 70 kDa protein, mitochondrial precursor, putative high abundance 52.89%
Tc00.1047053510955.40 axoneme central apparatus protein, putative 42.15%
Tc00.1047053511215.119 69 kDa paraflagellar rod protein, putative 23.97%
Tc00.1047053511271.10 dispersed gene family 1 fragment 4 unique to T. cruzi 5.08%
Tc00.1047053506529.610 hypothetical protein 17.27%
Tc00.1047053506391.30 EF-hand protein 5 2.48%
Tc00.1047053506635.130 hypothetical protein, conserved high abundance 68.60%
Tc00.1047053511265.10 dispersed gene family 1 fragment 5 unique to T. cruzi 8.62%
Tc00.1047053511289.30 aminopeptidase, putative 11.57%
Tc00.1047053506195.110 malate dehydrogenase, putative high abundance 24.79%
Tc00.1047053508461.140 poly(A)-binding protein high abundance 34.17%
Tc00.1047053508441.20 glycosomal phosphoenolpyruvate carboxykinase, putative high abundance 59.29%
Tc00.1047053508355.250 60S acidic ribosomal subunit protein, putative high abundance 75.21%
Tc00.1047053511633.79 microtubule-associated protein homolog high abundance 74.38%
Tc00.1047053510433.20
Tc00.1047053504277.11
Tc00.1047053504157.130
TolT proteins unique to T. cruzi 74.38%
Tc00.1047053411235.9 alpha tubulin
Tc00.1047053510877.30 hypothetical protein, conserved
Tc00.1047053509695.220 serine carboxypeptidase (CBP1), putative
Tc00.1047053510887.50 hypothetical protein, conserved
Tc00.1047053509141.40 hypothetical protein, conserved
Tc00.1047053506247.220 histidine ammonia-lyase
Tc00.1047053509995.10 60S ribosomal protein L4, putative
Tc00.1047053504163.50 fructose-bisphosphate aldolase, glycosomal, putative
Tc00.1047053507089.270 dihydrolipoyl dehydrogenase, putative
Tc00.1047053511019.90 iron superoxide dismutase, putative
Tc00.1047053509017.20 hypothetical protein, conserved
Tc00.1047053506529.360 cytochrome C oxidase subunit IV, putative
Tc00.1047053510187.50 tyrosine aminotransferase, putative
Tc00.1047053505989.110 hypothetical protein, conserved
Tc00.1047053508209.140 protein disulfide isomerase, putative
Tc00.1047053506531.20 hypothetical protein, conserved
Tc00.1047053504153.280 hypothetical protein, conserved
Tc00.1047053509233.180 ATPase beta subunit, putative
Tc00.1047053506563.40 beta tubulin
Tc00.1047053506459.290 elongation factor-1 gamma, putative
Tc00.1047053508707.200 nucleoside diphosphate kinase, putative
Tc00.1047053506529.460 hypothetical protein, conserved
Tc00.1047053506297.270 60S ribosomal protein L28, putative
Tc00.1047053511527.34 60S ribosomal protein L2, putative
Tc00.1047053507483.4 polyubiquitin, putative
Tc00.1047053509053.70 p22 protein precursor, putative
Tc00.1047053506585.40 glucose-regulated protein 78, putative
Tc00.1047053511185 dispersed gene family 1 fragment 8
Tc00.1047053511589.130 14-3-3 protein, putative
Tc00.1047053511167.90 14-3-3 protein, putative
Tc00.1047053507241.30 arginine kinase, putative
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seronegatives who were born in an endemic region, and in 5
individuals who had cardiopathologies consistent with Chagas
disease. Lastly, testing in the multiplex assay of sera classified as
‘‘positive discordant’’ (based upon reactivity on 2 of the 3
conventional serologic tests but negative on the 3
rd test) confirmed
the positive diagnosis in all 7 cases with reactivity evident on 2–6
recombinant proteins by each serum. Without a clear gold
standard diagnostic it is not possible certify on a case-by-case basis
that the multiplex assay more accurately detects infection than
does conventional serology - particularly in cases where there is
reactivity to only 1 or 2 proteins and near the .4 S.D. cutoff. And
while the birth place and presence of heart disease may support a
positive diagnostic test, these criteria do not appear to distinguish
between those likely to have reactivity with one or more
recombinant proteins in the selected panel and those who do
not react. However it is clear that conventional serological tests fail
to detect a substantial number of individuals, many with
antibodies to multiple T. cruzi antigens. It is noteworthy that
screening of sera with a parasite lysate also routinely fails to detect
sera that exhibit reactivity to multiple recombinant T. cruzi
proteins. The set of 4 most frequently recognized proteins detected
all 7 of the discordant positive samples as well as 13 of the 15
discordant negative or negative samples that reacted with at least 1
protein. Expanding the panel to the 7 proteins that detected all of
the seropositive samples (see above) allowed us to detect all of these
15 questionable ‘‘negative’’ samples.
Monitoring treatment efficacy
Thereis a pressing need for a means to assesstreatment efficacyin
Chagas disease so we next used the mulitplex assay to monitor
changes in serology over time in subjects treated with benznidazole
(BZ). Representative data from a set of 16 non-endemic normals
(Figure 5A) demonstrates the background level of detection of
responses in uninfected individuals, displayed as the MFI for each
protein.Toestablishthestabilityofserologicalresponsesovertimein
the absence of treatment, serial serum samples were obtained from
chronically infected, seropositive subjects, all without clinical disease;
a representative set of 6 subjects screened at 4 times points for up to
21 months is shown in Figure 5B. Each subject exhibits a distinct
patternofserologicalresponsesand boththepatternandthepotency
of those responses are remarkably stable over time. In contrast, a
representative set of 4 (from a total of 38) subjects followed for up to
36 months after treatment with BZ shows that some subjects exhibit
a post-treatment decreaseinthe strengthof responsestomostT.cruzi
antigens tested (Figure 6A). In many cases this fall is evident by 2
months post-treatment (e.g. PP001, PP115, PP164) and is followed
by a transient increase at 6 months. Interestingly, this early drop in
antibody levels following treatment is also sometimes evident,
although less consistently so, with conventional serological tests,
particularly with indirect hemaglutination (Figure 6A). Subject
PP117 has borderline positive serology in both the multiplex and the
conventional serologic assays and is representative of a case in which
documenting changes following treatment would be difficult.
Figure 6A). Figure 6B presents 2 other patterns of responses
following treatment. PP044 shows essentially no change in the
pattern or potency of antibody responses up to 24 months post-
treatment. Subject PP024 is similar in that responses to the several
prominently detected proteins are relatively stable over time.
However the MFI reading for numerous other antigens falls
consistently over the 24 month monitoring period. Thus, although
itmighttakemoretime andadditionalassaystodeterminetreatment
efficacyinthesetwo subjects,a preliminary assessment wouldbethat
treatment failed in the case of PP044 but was successful for subject
PP024. A separate manuscript describing in greater detail both the
cellular and serological responses to T. cruzi flowing BZ treatment is
currently in preparation (Laucella, et al., in preparation).
Discussion
The poor quality of diagnostics for T. cruzi infection is a major
impediment to coping with a disease that affects as many as 20
Gene Id Gene name(s) Notes
% reactive with 121
known positive sera
Tc00.1047053510579.70 nascent polypeptide associated complex subunit, putative
Tc00.1047053506925.300 cyclophilin a
Tc00.1047053509775.40 iron superoxide dismutase, putative
Tc00.1047053503583.40 trans-splicing factor, putative
Tc00.1047053510099.120 d-isomer specific 2-hydroxyacid dehydrogenase-protein, putative
Tc00.1047053507093.300 hypothetical protein, conserved
Tc00.1047053508479.340 succinyl-CoA synthetase alpha subunit, putative
Tc00.1047053509815.120 dispersed gene family 1 fragment 9
Tc00.1047053511727.270 RNA-binding protein, putative
Tc00.1047053503781.80 universal minicircle sequence binding protein (UMSBP), putative
Tc00.1047053506201.39 translation elongation factor 1-beta, putative
Tc00.1047053506815.20 hypothetical protein
Note: Tc00 numbers indicate closest homologue(s) present in the T. cruzi CL Brener sequence database (TcruziDb.org) based upon sequencing of the genes (for top 16)
or predicted based upon primer sequences used in cloning. Because some primers for PCR cloning were designed prior to the release of the T. cruzi CL Brener sequence
(25) and the cloning involved the pooling of multiple clone derived from the PCR of a mixture of T. cruzi strains (see Material and Methods), some proteins were derived
from mixtures of genes (e.g. numbers 1 and 16) and/or had a percent sequence identity ,100% relative to the CL Brener strain (range 94.7 to 100%). In some cases (e.g.
# 5 and 9) genes.2 kb in length were cloned in ,2 kb fragments in order to facilitate cloning and protein production. Items listed in bold type were selected for
screening using .100 individual sera. Items underlined were selected to be part of the final 16 set bead array for screening of discordant sera or sera from subjects post-
treatment with benznidazole.
doi:10.1371/journal.pntd.0000316.t001
Table 1. cont.
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disease burden is at best a guess, the ability to conclusively identify
who should be treated, or should be allowed to donate blood or
tissues is greatly compromised and the effectiveness of interven-
tions to limit transmission or drugs to treat those infected is
impossible to determine with any certainty.
In the early stages of T. cruzi infection, parasites can often be
detected in blood. However, as immunity develops, even amplifica-
tion techniques such as xenodiagnosis, hemaculture, and PCR,
despite being repeated multiple times, routinely fail to detect
infection [12,18,32,33]. Consequently, determination of infection
status is largely dependent on the consensus results of multiple tests
with different formats (e.g. ELISA, indirect fluorescent antibody,
indirect hemaglutination, complement fixation). However the
unreliability of these tests is well documented [9,10,11,12,13,14,
15,16,17,18,19]. Many of these tests, including one recently licensed
by the United States Food and Drug Administration for use as a
blood screening test in the U.S. [20], use crude or semi-purified
parasite preparations derived from parasite stages present in the
insect vector but not in infected humans. Recently, a number of
recombinant parasite proteins or peptides have also come into
limited use for diagnosis [21,22,34,35].
A subject whose serum is consistently positive on multiple of the
currently used tests is relatively easily determined to be infected. But
the infection status of individuals positive on only one test (as used in
blood bankscreening)isunclearand detection ofparasitesinsubjects
who are negative using multiple conventional serologic tests
[10,16,17,18,36] or who are positive by alternative but not widely
available serological tests [13,19] is not uncommon. Furthermore,
currently available tests are inadequate for monitoring treatment
efficacy [37,38,39] and thus may also give inaccurate measurements
of the effectiveness of other interventions.
With these deficits in mind, we set out to identify parasite
proteins that would more effectively detect T. cruzi infection and
provide a tool for monitoring changes in infection status over time.
Development of a repository of nearly 1500 T. cruzi genes cloned
into Gateway entry vectors provided a relatively straightforward
approach to producing a large number and diversity of T. cruzi
proteins appropriate for high-throughput screening of diagnostics.
Adding the targeted approach of selecting proteins documented
for high level expression in trypomastigote and amastigote stages
of T. cruzi allowed us to also focus on the proteins that would be
predicted to elicit the strongest antibody response in infected
humans. The Luminex-based multiplex bead array system
Figure 3. Reactivity of a representative set of proteins tested with individual sera. A selection of 29 individual recombinant proteins was
tested for the ability to bind IgGs present in the sera of 54 subjects. The sera are grouped as ‘‘uniformly positive’’ (reactive on all three conventional
serological tests and a commercial assay kit), ‘‘inconclusive’’ (negative on at least one conventional serologic tests), ‘‘negative by conventional tests’’
(negative by all three conventional tests), and ‘‘known negative’’ (from residents of North America with very low chance of being infected based upon
residency and travel history). Recombinant ovalbumin and T. cruzi lysate –coated beads were used as negative and positive controls, respectively.
Horizonal bars in each box indicate mean fluorescence intensity (MFI) on a scale from 0 to 30,000 arbitrary light units. A number of the recombinant
proteins either failed to discriminate between uniformly positive and known negative sera sets (e.g. 3, 16, 17, 22, 26, 27, 28) or showed no reaction
with either set (e.g. 10). In contrast a number of proteins detected nearly the entire uniformly positive group, as well as some in the inconclusive and
conventional negative groups but none in the known negative set (e.g. 4, 11, 14, 19 and 20 – stippled highlighting).
doi:10.1371/journal.pntd.0000316.g003
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requirements for serum. The production of histidine-tagged
proteins also made it relatively uncomplicated to attach the
recombinant proteins to Luminex beads. This latter point is not
trivial as the proteins could be coupled to the assay beads directly
from the urea-based denaturing lysis buffer without the require-
ment of movement to a non-denaturing buffer, wherein many of
the proteins precipitated. The strong response detected using
proteins prepared in this way suggests either that natively folded
proteins are not required for the detection of these antibodies, or
that re-folding of the proteins attached to the Luminex beads
during buffer exchange resulted in the formation of native
conformational epitopes.
In addition to its utility for screening of a large number of
proteins, the Luminex system also excels as a platform for
multiplex analysis of antibodies to a relatively large set of targets.
We were restricted in this work by the number of Luminex bead
sets manufactured with Ni+2 and thus sought to identify a
maximum of 16 independent T. cruzi proteins that gave
informative results from a large set of human sera. The ultimate
panel selected by the screen included at least one protein
previously identified as a potential diagnostic, the mitochrondrial
HSP-70 [40]. It is possible that other proteins revealed in our
screen have been studied previously. However since the identity of
some of these previously assayed proteins is somewhat cryptic [21]
and few have been associated with annotated genes in the
sequenced T. cruzi genome, this possibility is difficult to evaluate.
Also, over half of the antigens selected in our screen were among
the 50 most abundant proteins in the trypomastigote and
amastigote proteomes [31]. Two hypothetical proteins and 2
proteins unique to T. cruzi among the sequenced kinetoplastids,
including 2 fragments from the very large and multicopy dispersed
gene family protein, were among the proteins selected. Proteins
that are unique to T. cruzi could be particularly useful in a
Figure 4. Reactivity of negative, borderline or discordant sera in the 16 protein multiplex assay. Sera judged cumulatively as
‘‘seronegative’’ based upon conventional serology were grouped into negative but ‘‘no other evidence’’ of exposure (16 sera), those ‘‘born in an
endemic area’’ (12), those with evidence of ‘‘heart disease’’ consistent with Chagas disease (5) and compared to (top) pools of strongly positive sera
(high reactivity in all serological tests) and to (bottom) sera from subjects who were negative on at least one of the three conventional serologic tests
(discordant positive). Reactivity in the conventional serological tests (HAI, ELISA and IFI) and the summary consensus of these tests (neg=below cut-
off for all three tests; discord=positive on one of the three tests; discord +=positive on 2 of the 3 tests), as well as reactivity to the 16 recombinant
protein sets and the T. cruzi lysate are shown. Cutoffs for a positive ELISA is an O.D..0.200 and for IFA and HAI is a dilution.1/32 (a reaction at 1/16 is
considered ‘‘reactive but negative’’ and ,1/16 non-reactive (nr). The metric for reactivity of each serum for each protein is expressed as the number
of standard deviations that the ratio of the MFI for T. cruzi protein to the MFI for GFP was above the average ratios of sixteen true negative sera run in
the same assay. Values.4 S.D. above this ‘‘background’’ reactivity are considered reactive and are colored. The total number of reactive recombinant
proteins for each serum is indicated in the right-most column. nd=not determined (insufficient numbers of beads detected in this sample).
doi:10.1371/journal.pntd.0000316.g004
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potentially confounding infections in terms of diagnosis of T. cruzi.
However the dispersed gene family fragments were among the
worst performers in the large scale screen – with only 5–9% of all
confirmed positive sera having detectable antibodies to these.
Similarly, other gene family proteins, including trans-sialidases,
mucins and mucin-associated proteins (MASPS) were part of the
screen but failed to make even the initial selection cuts in our
assays, presumably because only a small fraction of their diversity
would be represented in the recombinant proteins screened.
A multiplex approach like the Luminex also provided a more
detailed examination of responses than is possible using a single
target consisting of either an individual protein or a protein/
peptide mixture. Each individual was seen clearly to have a
distinct pattern of responses to the protein panel and this pattern
was impressively stable over time (several years). This is both
interesting scientifically and serves as further validation of the
quality and consistency of the data generated using this multiplex
methodology. This heterogeneity of responses to pathogens among
individuals appears to be more the norm than the exception, as
similar results have been reported for individuals infected or
immunized with viral (vaccinia), bacterial (Francisella tularensis) and
protozoal (Plasmodium falciparum) pathogens [41,42,43]. Thus
serodiagnostics in general are likely to need to move toward
multiplex assays, as single antigens that are recognized by all
individuals infected by any pathogen appear to be rare [41].
The ability to simultaneously and independently assess antibody
responses to multiple targets was instrumental to our success in
addressing the issues of the detection of serological responses in
subjects who are negative by conventional serology and the
relatively rapid detection of changes in selected responses following
drug treatment. The multiplex assay detected 100% of 121
Figure 5. Stability of serological responses over time. The MFI of sera to a panel of 16 recombinant proteins (top 16 in Table 1), GFP negative
control protein and T. cruzi lysate for a total of 18 measurements (bars) are shown for each serum. A) Reactivity of a set of 8 known negative sera. B)
Stability of unique pattern of antigen activity for 6 seropositive subjects assayed at 4 time points over 12–21 months. Arrows in lower right panel (RD
07) indicate that detection of protein ‘‘8’’ (paraflagellar rod protein) which distinguishes the pattern of reactivity of serum RD07 from that of the
similar RD09.
doi:10.1371/journal.pntd.0000316.g005
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of samples positive on 2 out of 3 conventional tests. In addition,
however, we also detected antibodies specific for one or more
recombinant proteins in 18 of 33 subjects judged as negative by
conventional serology. Other investigators have documented cases
of conventional seronegative subjects being seropositive on
alternative tests or even parasite positive [10,13,16,17,18,19,36]
although these previous reports of ‘‘infected seronegatives’’ have
been somewhat anecdotal – presumably because investigators
rarely screen for parasites in seronegative subjects. However in
Figure 6. Effect of benznidazole treatment on serological responses in chronically infected subjects. The MFI of sera to a panel of 16
recombinant proteins (top 16 in Table 1), GFP negative control protein and T. cruzi lysate for a total of 18 measurements (bars) are shown for each
serum. A) Change in pattern of reactivity over 36 months post- benznidazole treatment in 4 subjects using both the multiplex serologic assay (left)
and conventional serology (right). B) Sera from 2 benznidazole-treated subjects exhibiting no evidence of change in multiplex assay for 24 months
post-treatment (left; PP044) and changes in reactivity to selected recombinant proteins (right; PP024).
doi:10.1371/journal.pntd.0000316.g006
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well documented. For example Picka et al. [18] reported on one
subject who was negative by up to 5 replicates of 4 different
conventional serological tests yet was positive by a combined
hemaculture-PCR approach. The multiple examples of the failure
of conventional serology to detect infection, in combination with
the well-documented unreliability of parasitological tests, supports
the conclusion that individuals who are seropositive in our
multiplex assay are likely to be infected with T. cruzi. This
conclusion is further supported by on-going studies demonstrating
T. cruzi –specific T cell responses in subjects who are negative by
conventional serology but positive in our multiplex assays (Postan,
et al. in preparation). Without more sensitive parasitological tests
we cannot conclusively determine if the subjects who are negative
by conventional serology but positive in our multiplex assay are
infected or possibly ‘‘exposed’’ but not still infected with T. cruzi.
And without additional extensive validation, we cannot exclude
the possibility that other infections or immunological conditions
resulted in some of the multiplex positive responses, although
standard clinical analysis failed to detect other complicating
infections in these subjects. However, especially for subjects who
have antibodies to up to 8 different recombinant T. cruzi proteins
and were born in endemic areas and/or have evidence of heart
disease, it is reasonable to conclude that they are indeed infected
with T. cruzi despite their negative results with conventional
serologic assays. Overall these studies support the already
documented conclusion that current serological tests can misdiag-
nose infection – perhaps to a significant extent.
A second issue we addressed using the multiplex serological
assay for T. cruzi infection was that of efficacy of therapeutic
treatment. Because most subjects are negative by parasitological
assays prior to treatment (making a negative result after treatment
uninformative) and remain positive by conventional serology for
extensive periods of time after treatment, assessing whether
treatment actually achieved cure, has been problematic. When
combined with other evidence of treatment failures and the
adverse effects of the drugs, the absence of a method to detect
treatment efficacy has resulted in a very low rate of treatment in
chronic Chagas disease. This absence of a reliable and timely test
for treatment efficacy is also a major impediment to the
development and testing of new drugs – an area that has been
at a virtual standstill for decades.
Herein we show that the multiplex assay using the selected set of
recombinant proteins can detect significant changes in antibody
levels, in some cases as early as the first post-treatment assay point
(2 months post-treatment completion). These changes are not
evident in all cases – an outcome that is not surprising given that
treatment failure is common [44]. Our ability to assess responses
to multiple targets on an individual basis appears to be crucial to
the success of detection of serologic changes following treatment,
as similar changes are not consistently observed using conventional
serologic tests. Previous studies have suggested that various
recombinant antigens may provide better assessment of treatment
efficacy relative to conventional serology [37,45]. Further studies
of a large set of treated subjects, using both multiplex serology and
cellular immune responses support the hypothesis that these
immunological markers are effective indicators of treatment
success or failure (Laucella, in preparation).
We define a set of diagnostic targets and an assay approach that
we believe is a significant improvement upon current diagnostic
tests for T. cruzi infection both for more consistently detecting
infection and for assessing the effectiveness of treatment.
Additional validation of these targets and the general methodology
will require analysis of a larger set of subjects, a process that is
currently on-going. Herein we have also not addressed the
question of whether the antigens we identify would be useful
throughout the wide endemic range for T. cruzi. Heterogeneity
among different parasites strains in distinct regions could present a
challenge. However here again this is a concern that a multiplex
assay might rather easily address – it seems unlikely that all 16
proteins in our pool, most of which are abundant housekeeping
proteins, would vary substantially among parasites in various
regions. Furthermore, we have intentionally used a mixture of T.
cruzi strains from geographically distinct regions as the source of
genes encoding the proteins used in these studies, with the goal of
capturing some of the heterogeneity that may exist in these
proteins among various parasite isolates.
The problem of infection confirmation by detection of parasites
or parasite products is likely to continue to be a roadblock to full
acceptance of the results of this test, or any other, when they
conflict with conventional serologic tests – despite the proven
inadequacy of these ‘‘standard’’ tests. Currently there is no
methodology that allows for the consistent detection of parasites or
their products in chronically infected hosts. The well-documented
failure of various PCR-based approaches indicates that even
highly abundant T. cruzi sequences are insufficient to document
active infection in the majority of individuals, in addition to
confirming the very low level of parasite persistence in most
individuals. If the million-fold amplification afforded by PCR is
unable to consistently reveal persistent T. cruzi infection, it also
seems that detection of other parasite ‘‘biomarkers’’ will be equally
inadequate. One advantage of using host biomarkers such as
pathogen-specific antibodies and T cells is that they are naturally
and endogenously self-amplified in the course of immune
recognition of the infection. Downsides of the Luminex system
for multiplex analysis include the reagent expense as well as the
requirement for specialized equipment to ‘‘read’’ the results.
However, other multiplex platforms such as protein microarrays
could be more cost conservative and require less infrastructure
[41,46]. Also, our results suggest that the number of proteins in the
analysis could be reduced without substantial loss of sensitivity,
and the possibility exists for additional improvements in sensitivity
by the inclusion of T. cruzi proteins previously validated by others
or that could be detected in additional screens like that described
herein. At a minimum, these results begin to lay the groundwork
for the removal of one of the major impediments to the
development and effective implementation of treatments for T.
cruzi infection.
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